Antiviral Drugs for the Treatment of Hepatitis C

Hepatitis C is a blood-borne viral infection that can progress from chronic liver inflammation to cirrhosis, liver failure, and hepatocellular carcinoma. The treatment landscape is centered on oral direct-acting antiviral regimens, which target viral proteins and can cure infection in most appropriately treated patients. Public-health value depends not only on clinical efficacy, but also on diagnosis, linkage to care, affordable access, treatment completion, and confirmation of sustained virologic response after therapy.

Treatment has shifted from interferon-based regimens with substantial tolerability and monitoring burdens toward shorter, better-tolerated, pangenotypic oral therapies. This transformation has simplified care for many patients, reduced dependence on genotype-specific selection, and enabled treatment outside highly specialized settings. Remaining challenges include finding undiagnosed infections, assessing liver disease and drug interactions, addressing reinfection risk, and maintaining supply and reimbursement pathways for underserved populations.

Artificial intelligence can support hepatitis C programs by identifying people who may need testing from clinical records, prioritizing abnormal liver-related results for follow-up, and improving patient navigation. It may also assist with adherence reminders, treatment-interaction screening, and population-level monitoring. These applications require representative data, clinical validation, privacy safeguards, explainability, and human oversight. AI should strengthen established testing and treatment pathways rather than substitute for confirmatory diagnostics or clinician judgment.

North America combines strong diagnostic and therapeutic capabilities with persistent gaps among uninsured, rural, incarcerated, Indigenous, and other vulnerable populations. Latin America is expanding access unevenly, with affordability, procurement, and diagnosis remaining important constraints. Europe benefits from mature clinical infrastructure, but progress differs across countries and affected communities. The Middle East faces varied screening and health-system capacity, while Africa carries a substantial burden with major opportunities for simplified testing, decentralized care, and pooled procurement. Asia-Pacific spans advanced treatment systems and large populations where case finding, affordability, and rural access remain central priorities.

ASEAN countries can benefit from regional procurement collaboration, laboratory strengthening, and differentiated service delivery for mobile and underserved populations. BRICS members represent diverse epidemiological and health-system settings, making domestic production, generic access, and scalable screening important themes. European Union coordination supports shared public-health objectives while national reimbursement and implementation remain decisive. G7 systems generally possess advanced diagnostics and medicines but must address inequities in reach. GCC countries can leverage centralized health systems and targeted screening, while NATO members vary considerably and should align communicable-disease preparedness with civilian hepatitis services.

Australia has emphasized elimination-oriented testing and treatment among priority populations. Brazil’s priorities include decentralized diagnosis, public-sector access, and continuity of care. Canada must improve reach among Indigenous, remote, and marginalized communities. China is focused on broadening diagnosis and affordable treatment within a large and diverse health system. France, Germany, Italy, Spain, and the United Kingdom combine established clinical capacity with ongoing efforts to close testing and linkage gaps. India faces major needs in screening, affordability, and delivery across its large population. Japan and South Korea have strong medical infrastructure but continue to require systematic case finding and care for aging or higher-risk groups. Mexico’s progress depends on expanding diagnosis, financing, and access beyond major urban centers. Russia requires sustained detection, treatment availability, and reliable surveillance across geographically dispersed populations. In the United States, insurance, fragmented care, and low diagnosis rates remain important barriers despite broad therapeutic capability.

Industry leaders should prioritize evidence-based access strategies: support reflex or simplified testing pathways, improve affordability and responsible supply continuity, and provide tools that help clinicians assess liver disease and drug interactions. Partnerships with public-health agencies and community organizations can strengthen outreach to people who inject drugs, incarcerated populations, migrants, rural communities, and others at elevated risk. Patient-support programs should emphasize treatment initiation, completion, post-treatment confirmation, and reinfection prevention. Digital and AI-enabled solutions should be introduced only with validated performance, transparent governance, and measurable effects on diagnosis and cure.

This executive summary synthesizes established clinical, epidemiological, regulatory, and public-health evidence concerning hepatitis C and antiviral treatment. The assessment considers disease burden and progression, direct-acting antiviral clinical use, testing and linkage pathways, access and reimbursement conditions, health-system capacity, and regional implementation barriers. Geographic comparisons are qualitative and reflect differences in policy, infrastructure, population needs, and delivery models. No market estimates, market shares, forecasts, or company-specific claims are used. Findings should be interpreted alongside current national guidelines, regulatory information, and locally validated surveillance data.

The central opportunity in hepatitis C is to convert highly effective oral antiviral therapy into consistent population-level diagnosis, treatment, cure confirmation, and prevention of reinfection. Progress will depend less on therapeutic innovation alone than on coordinated implementation: accessible testing, simplified care, equitable financing, reliable procurement, trained providers, and trusted community engagement. Leaders who connect clinical quality with measurable public-health outcomes can help close the gap between what treatment can achieve and what health systems currently deliver.